Protagonist Therapeutics initiates Phase IIb trial of PTG-100 to treat ulcerative colitis

US-based clinical-stage biopharmaceutical company Protagonist Therapeutics has initiated its Phase IIb clinical trial of PTG-100 to treat ulcerative colitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news